Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for aggressive non-Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single-center retrospective study

Diffuse large B-cell lymphoma in the elderly: Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) Expert Position Paper

(2015) Vicki A. Morrison et al.   Journal of Geriatric Oncology

The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma

(2014) Huei-Ting Tsai et al.   LEUKEMIA & LYMPHOMA

Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity

(2013) Marzia Lotrionte et al.   AMERICAN JOURNAL OF CARDIOLOGY

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

(2013) Z. Zhou et al.   BLOOD

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study

(2013) Cindy Varga et al.   LEUKEMIA & LYMPHOMA

Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy

(2012) Scott F. Huntington et al.   LEUKEMIA & LYMPHOMA

Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma

(2011) S. A. M. van de Schans et al.   ANNALS OF ONCOLOGY

The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age

(2011) S. Mareschal et al.   HAEMATOLOGICA

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

(2011) Frédéric Peyrade et al.   LANCET ONCOLOGY

Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi

(2011) Francesco Merli et al.   LEUKEMIA & LYMPHOMA

Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

(2010) Sharon Barrans et al.   JOURNAL OF CLINICAL ONCOLOGY

Troponin I Provides Insight Into Cardiotoxicity and the Anthracycline-Trastuzumab Interaction

(2010) Michael S. Ewer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial

(2009) S. Luminari et al.   ANNALS OF ONCOLOGY

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma

(2009) Yoshiki Terada et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The Utility of 18-F-Fluorodeoxyglucose Positron Emission Tomography in Evaluation of Bone Marrow Involvement by Non-Hodgkin Lymphoma

(2008) Alaa A. Muslimani et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study

(2008) Giuseppe Visani et al.   LEUKEMIA & LYMPHOMA